Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

S Badve, DJ Dabbs, SJ Schnitt, FL Baehner… - Modern …, 2011 - nature.com
Breast cancer is a heterogeneous disease encompassing a variety of entities with distinct
morphological features and clinical behaviors. Although morphology is often associated with …

Triple-negative breast cancer: recent treatment advances

ART Bergin, S Loi - F1000Research, 2019 - pmc.ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to
affect younger women, metastasise early despite optimal adjuvant treatment and carry a …

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani… - Nature, 2017 - nature.com
The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new …

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

BD Lehmann, JA Bauer, JM Schafer… - Breast Cancer …, 2014 - Springer
Introduction Triple negative breast cancer (TNBC) is a heterogeneous collection of
biologically diverse cancers, which contributes to variable clinical outcomes. Previously, we …

Triple-negative breast cancer: role of specific chemotherapy agents

SJ Isakoff - The Cancer Journal, 2010 - journals.lww.com
Cytotoxic chemotherapy remains the mainstay of treatment for triple-negative breast cancer
(TNBC) despite the promise of new targeted and biologic agents. Many studies have shown …

[HTML][HTML] Triple negative breast cancer: a mountain yet to be scaled despite the triumphs

Q Wu, S Siddharth, D Sharma - Cancers, 2021 - mdpi.com
Simple Summary Triple-negative breast cancer (TNBC) is a highly aggressive subtype of
breast cancer that cannot be treated with endocrine therapy and Her2-targeted therapy …

[PDF][PDF] Triple negative breast cancer-prognostic factors and survival

T Ovcaricek, SG Frkovic, E Matos, B Mozina… - Radiology and …, 2011 - sciendo.com
Background. Triple negative breast cancer (TNBC) is defined by a lack of expression of both
estrogen (ER) and progesteron (PgR) receptors as well as human epidermal growth factor …

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis

B Keam, SA Im, KH Lee, SW Han, DY Oh, JH Kim… - Breast Cancer …, 2011 - Springer
Introduction Triple negative breast cancer (TNBC) has a poorer survival, despite a higher
response rate to neoadjuvant chemotherapy. The purpose of this study was to identify the …

[HTML][HTML] Management of triple negative breast cancer

C Oakman, G Viale, A Di Leo - The Breast, 2010 - Elsevier
Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer
cases. TNBC is an immunohistochemically defined subtype, with significant diversity within …

Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the US-a SEER analysis

M Kakarala, L Rozek, M Cote, S Liyanage, DE Brenner - BMC cancer, 2010 - Springer
Background Recent reports suggest increase in estrogen receptor (ER), progesterone
receptor (PR) negative breast cancer yet little is known about histology or receptor status of …